Placebo for Dupilumab

OTHER3 trials

Sponsors

Sanofi, Stanford University, Pfizer

Conditions

AsthmaAtopic DermatitisFood AllergyHypersensitivityHypersensitivity, FoodPeanut AllergyPeanut Hypersensitivity

Phase 2

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

CompletedNCT03387852

Start: 2018-03-12End: 2019-08-07Updated: 2022-06-14

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

CompletedNCT03679676

Stanford UniversityFood Allergy, Hypersensitivity, Hypersensitivity, Food +2

Start: 2020-02-05End: 2025-05-02Updated: 2026-05-29

Phase 3

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Not yet recruitingNCT07783425

PfizerAtopic Dermatitis

Start: 2026-08-19End: 2029-06-05Target: 1375Updated: 2026-08-24

Related Papers

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

New England Journal of Medicine2021-10-27371 citations